years. Patients who responded to CCRT had lower local recurrence rates (5.9% vs. 55.6%; p = 0.002) and a greater curative resection rate (97.1% vs. 66.7%; p = 0.024). The complication rates of both groups were similar. Conclusion: Neoadjuvant CCRT gives locally advanced rectal cancer patients a more favorable result, with acceptable toxicity. [J Chin Med Assoc 2009;72(4):179-182] 
Introduction
Colorectal cancer is a common cancer and a major cause of morbidity and mortality worldwide. Middle to lower rectal cancer, a challenge for surgeons, is problematic. Surgical therapy for rectal cancer has evolved since Ernest Miles first described the abdominoperineal resection in 1908. 1 By the 1920s, he had reduced the recurrence rate from almost 100% to approximately 30%, 2 thus ensuring that this technique was the gold standard at that time while advocating extensive aggressive cancer therapy. In retrospect, it is perplexing that such extreme surgery was standard, given its considerable local failure rate and its potential to result in urinary, sexual, and gastrointestinal dysfunction. Several modifications were proposed to promote locoregional control and survival, with little success. 3, 4 Better suture material, as well as devices enabling lower anastomosis, led to a shift toward sphincter-saving approaches with respect to cancer of the rectum. Anterior resection replaced abdominoperineal resection as the mainstay of therapy, although adequate consideration of circumferential margins and lymph node harvests were often neglected in early reports in the 1950s. Not surprisingly, there was concern that sphinctersaving surgery might increase local recurrence. It was in this setting that total mesorectal excision (TME) was first described in 1982 by Heald and colleagues; 5 TME reduced recurrence rates to less than 10%. 6 Neoadjuvant concurrent chemoradiotherapy (CCRT), introduced in the last decade, has led to local control for advanced rectal cancer to a higher percentage of R0 resection (margin clear under microscopic examination) and a lower recurrence rate. Three of the patients, who achieved confirmed clinical complete response by CT scan and physical examination, and who received only local excision, were excluded, leaving 43 patients included in our study. Based on post-CCRT CT and digital rectal examination, we defined the clinical response. Five (12%) patients had complete response and 29 (67%) had partial response; the overall response rate was 79%. Several parameters, including local recurrence, curative resection (R0 resection), and postoperative complications, were evaluated. The method of statistical analysis for disease-free survival time and overall survival time was KaplanMeier survival analysis, whereas that for postoperative complications, metastasis, curative resection rate and Duke's stage was Fisher's exact test.
Results
Patients' characteristics are shown in Table 1 . Most of them received TME, and almost all had protective ileostomy. Curative resection rate (R0 resection rate) was higher in the responding group (97%) than in the non-responding group (66.7%), with statistical significance (p = 0.024). As shown in Table 2 , the local recurrence rate was low in the responding group (5.9%) compared with the non-responding group (p = 0.002). Disease-free survival was also higher in the responding group, with marginal statistical significance (p = 0.06). Otherwise, there was no significant difference between groups in overall survival time. The anastomotic leakage rate was high, up to 25% in both groups. Mean hospital stay was 11.5 days, with no significant difference between groups. As can be seen in Table 3 , the risk factors for local recurrence were high Duke grade and incomplete resection (R1 [microscopic margin positive] and R2 [gross margin positive] resection). Incomplete resection rate was higher in the non-responding group. During the period of CCRT, there was only 1 patient who developed grade III neutropenia, and no distant metastatic lesions occurred.
Discussion
Incomplete resection of rectal cancer eventually results in local recurrence and death. To improve this, Miles 1 introduced abdominoperineal resection in the early 1900s. With evolving instruments, a sphincter-saving procedure was performed in rectal cancer. Heald et al 5 developed TME in 1982, which decreased the local recurrence rate to less than 10%. In locally advanced rectal cancer, it remained a challenge until the early 1990s. Neoadjuvant CCRT 8, 9 offered the possibility of tumor-shrinking, hence making curative resection possible. In our series, 43 patients received neoadjuvant CCRT, with a mean follow-up time of 1.5 years. The overall recurrence rate was 16.3%, including 5.9% in the responding group and 55.6% in the non-responding group, respectively (p = 0.002). The curative resection rates were 97.1% in the responding group and 66.7% in the non-responding group, respectively (p = 0.024). It is well known that by inducing tumor shrinkage and hence leading to further curative resection, CCRT improved the local control rate. It could have caused other problems if we had saved the sphincter in the non-responding group. The anastomotic leakage rate was 27.8%, similar in both groups. As most of our patients had received protective ileostomy, the problem was solved and the mean hospital stay was only 11.5 days. *Data presented as mean ± standard deviation or n (%). TME = total mesorectal excision.
Neoadjuvant CCTR in rectal cancer In our study, major complications were acceptable: < 10%, similar to other series. 10 Thirty-two patients received sphincter-saving surgery, and 5 of them (15.6%) converted to permanent stoma. In our series, the toxicity related to CCRT was mild, as in other reports. There were 20-30% of patients who developed grade I-II nausea/vomiting and grade I-II neutropenia, and only 1 patient developed grade III neutropenia. No metastatic lesions occurred during the period of CCRT.
In conclusion, neoadjuvant CCRT gives a high chance of tumor shrinkage, and hence improves the curative resection and local control rates. Patients who responded to CCRT had a better local control rate with tolerable adverse effects.
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